Funded Biotechnology Startups in Menlo Park
Among the 27 most recent biotechnology funding entries tied to Menlo Park, the disclosed-round size distribution is highly top-heavy: Grail’s $390M round (…
Among the 27 most recent biotechnology funding entries tied to Menlo Park, the disclosed-round size distribution is highly top-heavy: Grail’s $390M round (2020-05-06) is the largest disclosed amount, and it dwarfs the next-largest disclosed figures shown, including 180 Life Sciences at $425M (2025-07-29) and the cluster in the ~$50M–$130M range (e.g., BillionToOne $130M on 2024-06-21, Adverum Biotechnologies $128M on 2024-02-05). The smallest disclosed amount is IncellDx at $500K (2024-07-23), creating a wide spread from sub-$1M to hundreds of millions.
Timing is concentrated toward recent years: the displayed rounds span 2020-05-06 through 2026-06-16 (Emmecell, undisclosed). Most rows share the same geography and sector label (all entries list “Biotechnology” and Menlo Park, California), while classification is uneven: there are 2 “undisclosed” amounts (Emmecell 2026-06-16; MedaSystems 2025-03-05; Ionpath 2022-05-11) plus multiple “Series Unknown” / blank series entries, including 2025-12-11 (Tivic Health $18M, Series Unknown) and 2026-03-09 (AN2 Therapeutics $40M, Series Unknown; Forum Markets $10M, Series Unknown).
Most recent rounds
27 shownRelated listings
Frequently asked
What does the largest disclosed round in this Menlo Park biotechnology list look like versus the rest?
The largest disclosed amount shown is 180 Life Sciences at $425M (2025-07-29). It sits well above the next-largest disclosed rounds, such as Grail’s $390M (2020-05-06), and both dwarf mid-tier disclosed amounts like TrueBinding $58M (2023-07-05) and Vortex Biosciences $4M (2023-06-22).
Are there date clusters among the most recent funding events?
Yes. March 2026 alone shows two Biotechnology entries on the same date (Forum Markets $10M and AN2 Therapeutics $40M on 2026-03-09). Separately, 2024 forms a dense stretch with multiple rounds between 2024-06-21 (BillionToOne $130M) and 2024-12-19 (Personalis $50M).
Which entries are the clear outliers on disclosed amount?
In the low end, IncellDx is at $500K (2024-07-23), far below most other disclosed rounds. On the high end, 180 Life Sciences ($425M on 2025-07-29) and Grail ($390M on 2020-05-06) are the most prominent scale outliers compared with many single-digit-to-tens-of-millions entries like Revelation Biosciences $9M (2021-01-05) and Vortex Biosciences $4M (2023-06-22).
How concentrated is the stage/series information in this slice?
Stage labeling is incomplete: several rounds use “Series Unknown” (e.g., Tivic Health $18M on 2025-12-11; Octave $40M on 2023-11-24; AN2 Therapeutics $40M on 2026-03-09), and at least three entries list “undisclosed” amounts (Emmecell 2026-06-16; MedaSystems 2025-03-05; Ionpath 2022-05-11). The result is a mix where disclosed sizes can’t always be cleanly mapped to a specific series for deals like Tivic Health and Octave.
What stage or sector pattern stands out given that all rows share the same city and sector label?
Geography and sector are fully aligned in the rows: every entry lists Biotechnology and Menlo Park, California. With that constraint, the main differentiator is disclosed round size and series granularity—for example, multiple large disclosed rounds with “Series Unknown” (AN2 Therapeutics $40M on 2026-03-09; Adverum Biotechnologies $128M on 2024-02-05) sit alongside clearly labeled rounds like Hexagon Bio $77M (Series B on 2023-02-13) and Synthekine $100M (Series C on 2023-01-06).
Which entries fall within the most recent quarter covered by the table’s date range?
Using the latest date shown (2026-06-16, Emmecell, undisclosed) as the endpoint, the most recent quarter window includes 2026-06-16 (Emmecell), plus 2026-03-09 rounds like AN2 Therapeutics $40M and Forum Markets $10M. The next step back in time visible in the dataset is 2026-02-25 (Abram Scientific $12M, Series A) and 2026-01-27 (Antheia $24M, Series C).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.